Inhibikase Therapeutics Inc

NASDAQ:IKT   1:04:07 PM EDT
0.83
-0.03 (-3.97%)
Products

Inhibikase Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Ikt-001Pro

Published: 08/26/2022 13:12 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for Ikt-001pro for the Treatment of Chronic Myelogenous Leukemia.
Inhibikase Therapeutics Inc - Look Forward to Initiating a Bioequivalence Study for Ikt-001pro in Second Half of 2022.